Litcius/Paper detail

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

Giacomo De Luca, Giulio Cavalli, Corrado Campochiaro, Emanuel Della‐Torre, Piera Angelillo, Alessandro Tomelleri, Nicola Boffini, Stefano Tentori, Francesca Mette, Nicola Farina, Patrizia Rovere‐Querini, Annalisa Ruggeri, Teresa D’Aliberti, Paolo Scarpellini, Giovanni Landoni, Francesco De Cobelli, John F. Paolini, Alberto Zangrillo, Moreno Tresoldi, Bruce C. Trapnell, Fabio Ciceri, Lorenzo Dagna

2020The Lancet Rheumatology209 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePneumoniaCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BlockadeProspective cohort studyImmunologyInternal medicineReceptorDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19